S1

Study or Subgroup	Risk Difference	SE	Weight	Risk Difference IV, Random, 95% CI
Ramesar 1987	0.636	0.073	7.1%	0.64 [0.49, 0.78]
Sossai 1990	0.366	0.046	8.2%	0.37 [0.28, 0.46]
Silva 1990	0.185	0.035	8.5%	0.18 [0.12, 0.25]
Fang 1991	0.58	0.047	8.1%	0.58 [0.49, 0.67]
Filipe 1994	0.477	0.016	8.9%	0.48 [0.45, 0.51]
Sun 2009	0.694	0.059	7.7%	0.69 [0.58, 0.81]
Gonzalez 2010	0.458	0.036	8.5%	0.46 [0.39, 0.53]
Gonzalez 2016	0.469	0.023	8.8%	0.47 [0.42, 0.51]
Pittayanon 2017	0.11	0.033	8.6%	0.11 [0.05, 0.17]
Chapelle 2020	0.178	0.045	8.2%	0.18 [0.09, 0.27]
Piazuelo 2021	0.462	0.032	8.6%	0.46 [0.40, 0.52]
Lee 2021	0.447	0.021	8.9%	0.45 [0.41, 0.49]
Total (95% CI)			100.0%	0.42 [0.34, 0.50]

Heterogeneity: Tau² = 0.02; Chi² = 227.24, df = 11 (P < 0.00001); I² = 95%
Test for overall effect: Z = 10.05 (P < 0.00001)

Supplemental Figure 1

Forest plots based on 12 studies. The fixed-effects estimated pooled prevalence of incomplete IM among patients with IM was 42% (95%CI, 34%–49%) and complete IM was 58% (95% CI, 50%–66%).

Supplemental Figure 2

Forest plots based on 12 studies. The fixed-effects estimated pooled prevalence of incomplete IM among patients with IM was 42% (95%CI, 34%–49%) and complete IM was 58% (95% CI, 50%–66%).

Supplemental Figure 3.

Forest plots based on 12 studies. In patients with incomplete IM, the fixed-effects estimated pooled prevalence of type II IM was 45% (95%CI, 41%–49%) and type III IM was 55% (95%CI, 51%–59%).

S4

Study or Subgroup	Risk Difference	SE	Weight	Risk Difference IV, Fixed, 95% CI
Ramesar 1987	0.5	0.094	4.2%	0.50 [0.32, 0.68]
Sossai 1990	0.463	0.078	6.1%	0.46 [0.31, 0.62]
Silva 1990	0.478	0.104	3.4%	0.48 [0.27, 0.68]
Fang 1991	0.477	0.062	9.7%	0.48 [0.36, 0.60]
Filipe 1994	0.583	0.023	70.2%	0.58 [0.54, 0.63]
Sun 2009	0.488	0.076	6.4%	0.49 [0.34, 0.64]
Total (95% CI)			100.0%	0.55 [0.51, 0.59]

Heterogeneity: Chi² = 6.10, df = 5 (P = 0.30); I² = 18%
Test for overall effect: Z = 28.66 (P < 0.00001)

Supplemental Figure 4

Forest plots based on 12 studies. In patients with incomplete IM, the fixed-effects estimated pooled prevalence of type II IM was 45% (95%CI, 41%–49%) and type III IM was 55% (95%CI, 51%–59%).